Insights into the Stress Response Triggered by Kasugamycin in Escherichia coli
AbstractThe bacteriostatic aminoglycoside antibiotic kasugamycin inhibits protein synthesis at an initial step without affecting translation elongation. It binds to the mRNA track of the ribosome and prevents formation of the translation initiation complex on canonical mRNAs. In contrast, translation of leaderless mRNAs continues in the presence of the drug in vivo. Previously, we have shown that kasugamycin treatment in E. coli stimulates the formation of protein-depleted ribosomes that are selective for leaderless mRNAs. Here, we provide evidence that prolonged kasugamycin treatment leads to selective synthesis of specific proteins. Our studies indicate that leaderless and short-leadered mRNAs are generated by different molecular mechanisms including alternative transcription and RNA processing. Moreover, we provide evidence for ribosome heterogeneity in response to kasugamycin treatment by alteration of the modification status of the stalk proteins bL7/L12. View Full-Text
- Supplementary File 1:
Supplementary (PDF, 621 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Müller, C.; Sokol, L.; Vesper, O.; Sauert, M.; Moll, I. Insights into the Stress Response Triggered by Kasugamycin in Escherichia coli. Antibiotics 2016, 5, 19.
Müller C, Sokol L, Vesper O, Sauert M, Moll I. Insights into the Stress Response Triggered by Kasugamycin in Escherichia coli. Antibiotics. 2016; 5(2):19.Chicago/Turabian Style
Müller, Christian; Sokol, Lena; Vesper, Oliver; Sauert, Martina; Moll, Isabella. 2016. "Insights into the Stress Response Triggered by Kasugamycin in Escherichia coli." Antibiotics 5, no. 2: 19.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.